Vincerx Pharma 관리

관리 기준 확인 4/4

Vincerx Pharma CEO는 Ahmed Hamdy, Dec2020 에 임명되었습니다 의 임기는 3.92 년입니다. 총 연간 보상은 $ 734.95K, 65.2% 로 구성됩니다. 65.2% 급여 및 34.8% 보너스(회사 주식 및 옵션 포함). 는 $ 437.31K 가치에 해당하는 회사 주식의 5.11% 직접 소유합니다. 437.31K. 경영진과 이사회의 평균 재임 기간은 각각 3.5 년과 3.8 년입니다.

주요 정보

Ahmed Hamdy

최고 경영자

US$735.0k

총 보상

CEO 급여 비율	65.2%
CEO 임기	3.9yrs
CEO 소유권	5.1%
경영진 평균 재임 기간	3.5yrs
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Ahmed Hamdy 의 보수는 Vincerx Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$38m
Dec 31 2023	US$735k	US$479k	-US$40m
Sep 30 2023	n/a	n/a	-US$46m
Jun 30 2023	n/a	n/a	-US$54m
Mar 31 2023	n/a	n/a	-US$61m
Dec 31 2022	US$1m	US$460k	-US$63m
Sep 30 2022	n/a	n/a	-US$58m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$49m
Dec 31 2021	US$615k	US$460k	-US$39m
Sep 30 2021	n/a	n/a	-US$49m
Jun 30 2021	n/a	n/a	-US$25m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$622k	US$15k	-US$17m

보상 대 시장: Ahmed 의 총 보상 ($USD 734.95K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 646.00K ).

보상과 수익: Ahmed 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Ahmed Hamdy (59 yo)

3.9yrs

테뉴어

US$734,953

보상

Dr. Ahmed M. Hamdy, M.D., is Co-Founder of Vincerx Pharma, Inc. (formerly known as Vincera Pharma, Inc.) and has been its Chief Executive Officer and Chairman of the Board since December 2020. He served as...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ahmed Hamdy	Co-Founder	3.9yrs	US$734.95k	5.11% $ 437.3k
Raquel Izumi	Co-Founder	3.9yrs	US$668.96k	0.26% $ 22.0k
Alexander Seelenberger	Chief Financial Officer	3.9yrs	US$565.67k	0.099% $ 8.5k
Tom Thomas	Founder	3.7yrs	US$3.16m	데이터 없음
John Byrd	Founder & Chairman of Scientific Advisory Board	no data	데이터 없음	4.82% $ 412.8k
Hans-Georg Lerchen	Chief Scientific Officer	3.7yrs	데이터 없음	데이터 없음
Gabriela Jairala	Vice President of Investor Relations & Corporate Communications and Chief of Staff	1.3yrs	데이터 없음	데이터 없음
Karen Quarford	Vice President of Quality Operations & Compliance	1.8yrs	데이터 없음	데이터 없음
Melissa Merrick	Senior Director of People & Culture and Head of Human Resource	3.3yrs	데이터 없음	데이터 없음
Beatrix Stelte-Ludwig	Executive Chief Development Officer	3.5yrs	데이터 없음	데이터 없음
Steven Bloom	Chief Business Officer	1.4yrs	데이터 없음	데이터 없음
Raj Dua	VP of Biologics Development and Manufacturing and Sr. VP of Chemistry & Manufacturing	1.4yrs	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: VINC 의 관리팀은 경험 ( 3.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ahmed Hamdy	Co-Founder	3.9yrs	US$734.95k	5.11% $ 437.3k
Raquel Izumi	Co-Founder	3.9yrs	US$668.96k	0.26% $ 22.0k
John Byrd	Founder & Chairman of Scientific Advisory Board	3.6yrs	데이터 없음	4.82% $ 412.8k
Francisco Salva	Independent Director	3.9yrs	US$69.14k	0% $ 0
Brian Druker	Independent Director	3.9yrs	US$47.89k	0.16% $ 14.0k
Anthony Tolcher	Member of Scientific Advisory Board	3.6yrs	데이터 없음	데이터 없음
Laura Bushnell	Independent Director	3.9yrs	US$52.89k	0.057% $ 4.9k
Ruth Stevens	Independent Director	3.5yrs	US$47.89k	0% $ 0
Howard Burris	Member of Scientific Advisory Board	3.6yrs	데이터 없음	데이터 없음
Ian Flinn	Member of Scientific Advisory Board	3.6yrs	데이터 없음	데이터 없음
Andre Goy	Member of Scientific Advisory Board	3.6yrs	데이터 없음	데이터 없음
John Lee	Independent Director	3.9yrs	US$47.89k	0.0024% $ 203.7

3.8yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: VINC 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

Vincerx Pharma 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Vincerx Pharma, Inc., Annual General Meeting, May 23, 2024

Vincerx Pharma, Inc. Announces Resignation of Board of Directors

High number of new and inexperienced directors

Founder recently bought US$56k worth of stock

Vincerx Pharma, Inc. Announces Departure of Hermes Garban as Chief Medical Officer, Effective on or Before August 6, 2022

Recent updates

Vincerx Pharma, Inc. Receives Extension from Nasdaq Stock Market LLC to Meet the Exchange's Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Market cap size

Price target decreased by 14% to US$6.00

Vincerx Pharma, Inc. Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline

Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely

New major risk - Financial position

Insufficient new directors

New major risk - Negative shareholders equity

New minor risk - Shareholder dilution

Vincerx Pharma, Inc. has completed a Follow-on Equity Offering.

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering.

Vincerx Pharma, Inc., Annual General Meeting, May 23, 2024

New minor risk - Market cap size

Vincerx Pharma, Inc. Presents Positive Preliminary Phase 1 Data for Vip236 and Updates on Pipeline Progress At the American Association for Cancer Research (Aacr) Annual Meeting 2024

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 35% to US$9.00

New major risk - Share price stability

Vincerx Pharma, Inc. Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

New major risk - Financial position

New major risk - Revenue and earnings growth

Vincerx Pharma Receives Non-Compliance Notice from the Nasdaq Stock Market

Vincerx Pharma Receives Non-Compliance Notice from the Nasdaq Stock Market

Vincerx Pharma, Inc. Announces FDA Clearance of IND for VIP943

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

New major risk - Financial position

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Vincerx Pharma, Inc. Announces Resignation of Board of Directors

Vincerx Pharma Announces Fda Safe to Proceed Letter for Investigational New Drug (Ind) Application for Its <Alpha>V<Beta>3 Small Molecule-Drug Conjugate (Smdc) Vip236

Price target decreased to US$8.40

Vincerx Pharma, Inc. Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Price target decreased to US$12.60

High number of new and inexperienced directors

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Founder recently bought US$56k worth of stock

Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell 2000 Growth Index

Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

Vincerx Pharma, Inc. Announces Departure of Hermes Garban as Chief Medical Officer, Effective on or Before August 6, 2022

Vincerx Pharma, Inc. Provides Clinical Updates

Price target decreased to US$21.33

High number of new and inexperienced directors

Vincerx, Inc., Annual General Meeting, May 26, 2022

Price target decreased to US$23.86

Price target decreased to US$26.57

High number of new and inexperienced directors

Founder recently bought US$65k worth of stock

Vincerx Pharma, Inc. Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

Independent Director recently bought US$126k worth of stock

Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021

Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors

Vincerx Pharma doses first patient in early-stage VIP152 cancer study

Independent Director has left the company

Vincerx Pharma, Inc. Announces Management Appointments

Vincerx Pharma, Inc., Annual General Meeting, May 13, 2021

Vincerx, Inc. Announces Executive Changes

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령